Gene Therapy Investors: Angels and VC Firms

RaiseHunt currently lists 162 Gene Therapy investors.

Both. 55 are angel investors putting in their own money, and 107 are people making investment decisions at 25 firms.

The largest concentrations are in London, New York and Boston.

Most list Seed and Series A among the rounds they take part in.

Every profile shows whether an email address is on file. The addresses themselves, along with AI matching and outreach, are in the RaiseHunt app.

Yes. The directory and every profile page are free to read. Matching your own startup against them requires an account.

No. A focus area is a signal of interest, not a restriction. Investors usually list several, and the useful question is whether their existing portfolio looks like the kind of company you are building.

It helps, mostly because it moves your email out of a crowded inbox. It is not a requirement. A cold message that shows you understand what someone has already backed, and why your company fits that pattern, gets read more often than a vague introduction from a distant contact.

Look at what they have already funded rather than what their profile says they like. Stage matters most, then sector, then geography. An investor who has never funded anything at your stage is unlikely to start with you, however well the sector lines up.

Longer than most first-time founders plan for. The work splits into building the list, running outreach, taking meetings, and closing, and each stage can stretch. Start before you need the money, not when the runway is short.

The team and the problem, in that order, before the product. Early on there is rarely enough traction to argue from numbers alone, so the question they are answering is whether these particular people are likely to work this problem out.

Several, in almost every case. A single backer concentrates the risk of the round collapsing if that one conversation goes cold, and a group brings more introductions later. Rounds are usually assembled from a lead plus others who follow.